539730 FREDUN

Fredun Pharmaceuticals Share Price

₹749.90 +12 (1.63%)

29 Dec, 2024 07:42

SIP TrendupStart SIP in FREDUN

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 2.18%
  • Over 3 Month -0.76%
  • Over 6 Month -13.99%
  • Over 1 Year -14.32%
SIP Lightning

Smart Investing Starts Here Start SIP with Fredun Pharmaceuticals for Steady Growth!

Invest Now

Fredun Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Fredun Pharmaceuticals Financials

Fredun Pharmaceuticals Technicals

EMA & SMA

Current Price
₹749.90
+ 12 (1.63%)
pointer
  • stock-down_img
  • Bullish Moving Average 10
  • stock-up_img
  • Bearish Moving Average 6
  • 20 Day
  • ₹742.81
  • 50 Day
  • ₹744.17
  • 100 Day
  • ₹761.42
  • 200 Day
  • ₹791.82

Resistance and Support

738.17 Pivot Speed
  • R3 781.83
  • R2 765.87
  • R1 754.13
  • S1 726.43
  • S2 710.47
  • S3 698.73

What's your outlook on Fredun Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Fredun Pharmaceuticals has an operating revenue of Rs. 389.12 Cr. on a trailing 12-month basis. An annual revenue growth of 26% is outstanding, Pre-tax margin of 6% is okay, ROE of 12% is good. The company has a reasonable debt to equity of 11%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 92 which is a GREAT score indicating consistency in earnings, a RS Rating of 26 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 57 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Fredun Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-26 Quarterly Results
2024-10-03 Others inter alia consider issue and allotment of Unsecured Foreign Currency ConvertibleBonds (FCCBs), in accordance with the provisions of the SEBI Regulations, 2018 and the Companies Act, 2013. alia, to consider a proposal for fund raising up to Rs.120 crores by way of further public offer, rights issue, debt issue, preferential issue or any other method.
2024-07-29 Quarterly Results
2024-05-07 Audited Results & Final Dividend
2024-02-14 Quarterly Results
Date Purpose Remarks
2024-09-23 FINAL Rs.0.70 per share(7%)Final Dividend
2023-09-22 FINAL Rs.0.70 per share(7%)Final Dividend

Fredun Pharmaceuticals F&O

Fredun Pharmaceuticals Shareholding Pattern

48.93%
1.59%
44.21%
5.27%

About Fredun Pharmaceuticals

  • NSE Symbol
  • FREDUN
  • BSE Symbol
  • 539730
  • Managing Director & CFO
  • Mr. Fredun Medhora
  • ISIN
  • INE194R01017

Similar Stocks to Fredun Pharmaceuticals

Fredun Pharmaceuticals FAQs

Fredun Pharmaceuticals share price is ₹749 As on 29 December, 2024 | 07:28

The Market Cap of Fredun Pharmaceuticals is ₹349.7 Cr As on 29 December, 2024 | 07:28

The P/E ratio of Fredun Pharmaceuticals is 19.8 As on 29 December, 2024 | 07:28

The PB ratio of Fredun Pharmaceuticals is 2.9 As on 29 December, 2024 | 07:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23